$ANVS News

Annovis to Attend the CTAD 2026 with Three Presentations

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease

Annovis Bio Consensus Price Target Lowered by 16.67% to $10.71

Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA

Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7

Annovis to Host Corporate Update Webinar on September 2, 2026

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate

Roth Capital Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendation

Roth Capital Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $8

Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850 Patients; Symptomatic Data Readout Expected In Q1 2027, and Disease-Modifying Data Readout Anticipated in Q1 2028

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Annovis Bio (ANVS) Price Target Decreased by 12.23% to 14.02

Annovis Bio Regains NYSE Listing Compliance

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

Annovis Bio Prices Underwritten Public Offering Of 7,895,000 Shares And Warrants To Purchase Up To 7,105,500 Shares At $1.90 Per Unit

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants